Shalby Ltd

Q1 FY26Healthcare Services

Shalby Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹153

Market cap₹1.7K Cr

P/E42.0

Updated23 Aug 2026

Read4 min read

The short version

Shalby MedTech's standalone revenue for Q1 FY '26 grew 271% YoY to INR18.24 crores; consolidated revenue up 74.2% YoY to INR30.8 crores. Shalby Limited expects double-digit consolidated top-line growth of around 12% to 15% for FY '26.

From Shalby Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Shalby MedTech's standalone revenue for Q1 FY '26 grew 271% YoY to INR18.24 crores; consolidated revenue up 74.2% YoY to INR30.8 crores.
Implant component sales increased by 228.4% YoY (9,317 units) in standalone and 65.4% YoY (14,076 units) consolidated in Q1 FY '26.
Expect double-digit top-line growth of around 12%-15% for the full FY '26.
Planned global launch of 2 new products in FY '26 and expansion into 4-5 new countries to increase market presence.
Focus on increasing market share in key markets like the US, India, Indonesia, and Japan through partnerships and training.
The orthopedic implant business aims to reach $100 million revenue in 4-5 years, overcoming supply chain challenges.

2 more points from Shalby Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Shalby Limited expects double-digit consolidated top-line growth of around 12% to 15% for FY '26.
EBITDA margins are anticipated to improve in line with revenue growth.
Implant business to see single-digit EBITDA margins in current and next year, improving to 20%-25% over 4 to 5 years.
Implant business revenue target of $100 million is maintained, expected to be achieved over 4-5 years due to supply chain and product development timelines.
Implant business expected to eventually contribute around 25% of overall profits, but not immediately.
Mature hospitals (10+ years) highly profitable with ~36% EBITDA margins; 5-10 year old hospitals expected to show higher growth momentum (20%+ growth).

2 more points from Shalby Ltd's call on margins

Pro opens every point from 15K+ earnings calls

See what Shalby Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Mumbai hospital project: Received Charity Commission approval; awaiting lease formalities and handover from the trust. Construction expected to start after regulatory approvals, with a project timeline of 3 to 3.5 years from handover.
Focus on orthopedic business expansion: Current investments targeted at building the orthopedic division, with plans to grow this segment significantly before exploring other medical devices such as oncology, ophthalmology, and dental in the long term.
Careful scaling of franchise/lightweight model: Being very selective with hospital partners to maintain quality and brand reputation; no rapid expansion to avoid past issues.
Continued investments in implant business: Capital being invested heavily currently, expected to lower in coming quarters as business turns profitable and scales towards a $100 million target over 4-5 years.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked

1Health X Platform₹903 Cr

Rev 1Mar 1

2Chandan Healthca₹583 Cr

Rev 1Mar 3

3₹58.8K Cr

Rev 2Mar 1

4₹1.7K Cr

Rev 2Mar 2

5₹580 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no explicit mention of any immediate plans for new fundraising through debt or equity in the transcript.
Amit Pathak mentions that debt is primarily related to the implant business, which will start becoming profitable in coming quarters, implying lower future capital needs.
Interest costs are expected to slightly decrease due to improved profitability and reduced investment requirements in the implant business.
No detailed comments on raising funds through equity.

2 more points from Shalby Ltd's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Shalby Limited. There is no specific discussion about order book status, pending orders, or related metrics in the Q1 FY '26 earnings conference call transcript (pages 5-21). The conversation primarily focuses on topics such as occupancy rates, implant business growth, government scheme receivables, competition, pricing strategies, EBITDA margins, hospital expansions, and operational matters. If you would like details on other specific aspects or another section of the document, please let me know!

Shalby Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Shalby Ltd's management said in earlier quarters

Others in Healthcare Services this season

Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Rainbow Childrens Medicare Ltd (Q1 FY26)
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…
Vijaya Diagnostic Centre Ltd (Q1 FY26)
Price increases contribute approximately 1.5% to 2% of the revenue growth. Key concall takeaways from Vijaya Diagnostic Centre Ltd's Q1 FY26 earnings call…

Compare:vs Apollo Hospitals Enterprise Ltd vs Fortis Health.vs Dr Lal Pathlabs Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shalby Ltd Q1 FY26 results?

What is Shalby Ltd share price analysis?

Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shalby Ltd planning capital expenditure?

Mumbai hospital project: Received Charity Commission approval; awaiting lease formalities and handover from the trust.

Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Revenue & Sales Performance

Profitability & Margins

Capital Expenditure Plans

Top-ranked in Healthcare Services

Fundraising & Capital Structure

Order Book & Pipeline

Shalby Ltd — Quarterly revenue & net profit

Continue your research

What Shalby Ltd's management said in earlier quarters

Others in Healthcare Services this season

Shalby Ltd and 15K+ more earnings calls,for less than your morning chai

Frequently Asked Questions

Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai